CTI signs contract with NerPharMa for long-term manufacture of pixantrone Cell Therapeutics today announced that it offers signed a manufacturing contract with NerPharMa DS , in Nerviano, Italy) for CTI’s drug applicant pixantrone.S. Both are planned for this year. On June 14 CTI announced, 2010 that the Italian Medicines Company , the nationwide authority responsible for medication regulation in Italy, got approved the service at NerPharMa for the production of pixantrone. ‘We are very happy to have reached an agreement with NerPharMa for the long-term produce of pixantrone,’ stated Craig W. Philips, President of CTI.’.Asuragen announces data from microRNA biomarker research on pancreatic cancer Asuragen, Inc. Announced today that data from a collaborative research with Johns Hopkins concerning microRNA biomarkers for make use of on pancreatic cyst liquid specimens was shown at the American Pancreatic Association Annual Getting together with being kept November 2-5, 2011 in Chicago. Around 3 percent of the united states people harbors an asymptomatic pancreatic cyst. The majority of those cysts are benign and will be handled conservatively by watchful waiting around.